Patient-derived Xenograft (PDX) Mouse Models 

Recapitulate the tumor and patient heterogeneity and response to treatment using patient-derived xenograft (PDX) mouse models     

Home » Oncology CRO Services » Patient-derived Xenograft (PDX) Mouse Models

InnoSer’s Patient-derived Xenograft (PDX) Mouse Models Services

Patient-derived xenograft (PDX) mouse models are established from resected tumor samples obtained from oncologic patients that are implanted and grown in immunodeficient mice. However, to fully recapitulate the intricacies between the immune system and the tumor microenvironment, humanized mouse models are recommended instead of immunodeficient mice. Patient-derived xenograft (PDX) mouse models represent the most clinically relevant and predictive tool in your drug development journey, recapitulating the tumor and patient heterogeneity, gene expression, and response to treatment.  

Therefore, experts from InnoSer’s immuno-oncology team recommend the use of PDX mouse models whenever you have carried out initial in vivo studies using cell line-derived (CDX) mouse models and wish to obtain more clinically relevant results. Accordingly, patient-derived xenografts are suitable for evaluating a range of therapies ranging from immunotherapy, antibody, antibody-drug conjugate, and gene therapies to small molecules (cytotoxic drugs). PDX models provide you with a highly predictive in vivo model for therapeutic efficacy evaluation.

Compared to other preclinical in vivo models, patient-derived xenograft models represent more robust models, requiring longer study timelines and the inclusion of different patient samples to capture your compound’s efficacy on patient heterogeneity.  

✓  Well-characterised parental samples (histopathology, hot spot analyses, mutational burden, treatment history, response to treatment). 

✓  Complementary in vitro assays using patient-derived organoids (tumoroids).  

On-request PDX expansion services.

PDX

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions most cost-effectively. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.  

Unlock the Right Tools for Your Research.

Let our team help you navigate InnoSer’s extensive biobank to find patient samples of interest, including detailed data on hotspot mutations, tumor growth curves, and treatment responses.

PDXO technical leaflet

Patient-derived Xenograft (PDX) Mouse Models Sample Data

Key Patient-derived Xenograft (PDX) Mouse Models Readouts

InnoSer's Recommended Readouts


Test the efficacy of your treatments using PDX mouse models with the following readouts: 

 

  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • Histopathology 

    The People Behind Your Research

    Céline Erens, PhD, Immunology Study Director

    An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.

    Yanick Fanton, PhD, Chief Scientific Officer

    As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.

    Oncology Board Members

    Prof. Dr. Esther Wolfs

    A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.

    Marije Slingerland

    MD, PhD Marije Slingerland

    A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.

    Stay Curious: More Articles to Explore

    Pancreatic Cancer PDX Models

    Pancreatic Cancer PDX Models

    Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...

    RENCA Mouse Mouse Model of Renal Cancer

    RENCA Mouse Mouse Model of Renal Cancer

    Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...

    Tumor microenvironment (TME) multiplex immunophenotyping analyses

    Tumor microenvironment (TME) multiplex immunophenotyping analyses

    The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.